Paintal et al. reported 2 cases of NF2mut RCC with dramatic response to immune checkpoint inhibitors (ipilimumab/nivolumab).6 Our findings of more frequent PD-L1 tumor and immune cell expression in NF2mut tumors support that these patients may benefit form immune checkpoint inhibitors. This evidence concerns the gene CD274 and renal cell carcinoma.